Global Market Report

Nasal Drug Delivery Technology Market Forecast 2020-2030

The Global Nasal Drug Delivery Technology Market is estimated at $44,385 m in 2019 and is expected to grow at a CAGR of 7.8% from 2020-2025. In 2019, the Global Nasal Drug Delivery Technology Market was dominated by the nasal sprays submarket which held 33.2% of the overall market.

SKU: PHA0549 Categories: , Tags: , , , , , , Code: PHA0549Pages: 185
Clear
← Back to category Medical Devices

Description

The Global Nasal Drug Delivery Technology Market is estimated at $44,385 m in 2019 and is expected to grow at a CAGR of 7.8% from 2020-2025. In 2019, the Global Nasal Drug Delivery Technology Market was dominated by the nasal sprays submarket which held 33.2% of the overall market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 185-page report you will receive 54 charts, all unavailable elsewhere.

The 185-page report provides clear detailed insight into the Global Nasal Drug Delivery Technology Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts from 2020 to 2030 for the Global Nasal Drug Delivery Technology market.

• Revenue and growth forecasts from 2020 to 2030 for the Global Nasal Drug Delivery Technology Market by the dosage form:
– Dosage Form: Nasal Sprays, Nasal Drops & Liquids, Nasal Gels, Nasal Powders
– Nasal Sprays: Non-pressurized Containers and Pressurized Containers

• Revenue and growth forecasts from 2020 to 2030 for the Global Nasal Drug Delivery Technology Market by System:
– Nasal Unidose Devices
– Nasal Bi Dose Devices
– Nasal Multi Dose Devices

• Revenue and growth forecasts from 2020 to 2030 for the Global Nasal Drug Delivery Technology Market by Application:
– Asthma
– Allergic and Non-Allergic Rhinitis
– Nasal Congestion

• Revenue and growth forecasts from 2020 to 2030 for the Global Nasal Drug Delivery Technology Market by End User:
– Hospitals
– Ambulatory Surgery Center
– Specialty Clinics
– Vaccination Centers

• Revenue and growth forecasts from 2020 to 2030 for the leading national markets:
– United States
– Canada
– Brazil
– Mexico
– Rest of Latin America
– Germany
– UK
– Italy
– France
– Spain
– Nordic
– Benelux
– Rest of Western Europe
– Russia
– Poland
– Rest of Eastern Europe
– Japan
– China
– India
– Australia & New Zealand
– ASEAN
– Rest of Asia-Pacific
– GCC Countries
– South Africa
– North Africa
– Rest of MEA

Nasal Drug Delivery Technology Market Forecast 2020-2030

• This report profiles the leading companies that market nasal drug delivery devices:
– 3M Company
– Becton, Dickinson and Company
– GlaxoSmithKline plc
– Johnson & Johnson
– Merck & Co., Inc.
– Pfizer Inc.
– Teleflex Incorporated
– Naveh Pharma Ltd.
– OptiNose US, Inc.
– Pendopharm
– AptarGroup, Inc.

• This report provides qualitative analysis of the Global Nasal Drug Delivery Technology market. This report discusses the Porter’s Five Forces Analysis, as well as the Drivers and Challenges of this market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Digital Wound Care Management market. You find data, trends and predictions.

Buy our report today Nasal Drug Delivery Technology Market Forecast: Nasal Sprays: Non-Pressurised Containers & Pressurised Containers, Nasal Drops & Liquids, Nasal Gels, Nasal Powders; Multi Dose Nasal Devices, Bi-Dose Nasal Devices, Unit Dose Nasal Devices; Allergic and Non-Allergic Rhinitis, Nasal Congestion, Asthma; Ambulatory Surgery Centres, Hospitals, Specialty Clinics, Vaccination Centres.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. REPORT OVERVIEW
1.1 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET OVERVIEW
1.2 WHY YOU SHOULD READ THIS REPORT
1.3 HOW THIS STUDY DELIVERS
1.4 MAIN QUESTIONS ANSWERED BY THE ANALYSIS
1.5 WHO IS THIS INVESTIGATION FOR?
1.6 METHOD OF RESEARCH AND ANALYSIS
1.7 FREQUENTLY ASKED QUESTIONS (FAQS)
1.8 ABOUT VISIONGAIN

2. INTRODUCTION TO NASAL DRUG DELIVERY TECHNOLOGY MARKET
2.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET STRUCTURE
2.1.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET DEFINITION
2.1.2 NASAL DRUG DELIVERY ROUTE

3. GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET 2019-2030
3.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET DYNAMICS
3.2 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET DRIVERS AND CHALLENGES 2019
3.2.1 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET DRIVERS 2019
3.2.1.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES
3.2.1.2 GROWING ADOPTION OF SELF-ADMINISTRATION PRACTICES
3.2.1.3 RAPIDLY AGEING POPULATION
3.2.1.4 INCREASING PREFERENCE FOR NASAL DRUG DELIVERY ROUTE
3.2.1.5 INCREASING APPLICATIONS OF NASAL DRUG DELIVERY TECHNOLOGY
3.2.1.6 TECHNOLOGICAL ADVANCEMENTS IN NASAL DRUG DELIVERY
3.2.1.7 BI-DIRECTIONAL NASAL DRUG DELIVERY
3.2.2 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET CHALLENGES 2019
3.2.2.1 COMPLICATIONS OF OVERUSE OF NASAL SPRAYS AND NASAL POWDERS
3.2.3 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET OPPORTUNITIES 2019
3.2.3.1 OVER-THE-COUNTER (OTC) NASAL DRUGS
3.2.3.2 NOSE-TO-BRAIN DRUG DELIVERY ROUTE
3.2.3.3 EMERGING MARKETS
3.2.3.4 PRODUCT LAUNCHES IN THE NASAL DRUG DELIVERY TECHNOLOGY MARKET
3.3 REGULATION OF MEDICAL DEVICES
3.3.1 THE US APPROVAL AND REGULATION SYSTEM
3.3.2 THE EU APPROVAL AND REGULATION SYSTEM
3.3.2.1 POST-MARKETING SURVEILLANCE IN THE EU
3.4 PORTER'S FIVE FORCES ANALYSIS
3.4.1 BARGAINING POWER OF THE SUPPLIERS
3.4.2 BARGAINING POWER OF THE BUYERS
3.4.3 THREAT OF NEW ENTRANTS
3.4.4 HIGH INTENSITY OF RIVALRY
3.4.5 THREAT OF SUBSTITUTES

4. GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET BY DOSAGE FORM FORECAST 2020-2030
4.1 NASAL SPRAYS MARKET 2020-2030
4.1.1.1 NASAL SPRAYS MARKET FOR PRESSURIZED CONTAINERS 2020-2030
4.1.1.2 NASAL SPRAYS MARKET FOR NON-PRESSURIZED CONTAINERS 2020-2030
4.2 NASAL DROPS & LIQUIDS MARKET 2020-2030
4.3 NASAL GELS MARKET 2020-2030
4.5 NASAL POWDERS MARKET 2020-2030

5. GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET BY SYSTEM FORECAST 2020-2030
5.1 UNIT DOSE NASAL DRUG DELIVERY SYSTEM MARKET 2020-2030
5.2 BI-DOSE DOSE NASAL DRUG DELIVERY SYSTEM MARKET 2020-2030
5.3 MULTI-DOSE NASAL DRUG DELIVERY SYSTEM MARKET 2020-2030

6. GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET BY APPLICATION FORECAST 2020-2030
6.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ASTHMA 2020-2030
6.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ALLERGIC & NON-ALLERGIC RHINITIS 2020-2030
6.3 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR NASAL CONGESTION 2020-2030
6.4 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS 2020-2030
6.5 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS FORECAST 2020-2030

7. GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET BY END USER FORECAST 2020-2030
7.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR AMBULATORY SURGERY CENTERS (ASCS) 2020-2030
7.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS 2020-2030
7.3 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR SPECIALTY CLINICS 2020-2030
7.4 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR VACCINATION CENTERS 2020-2030

8. LEADING NATIONAL MARKETS 2020-2030
8.1 NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8. 1.1 US NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.1.2 CANADA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.2 LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.2.1 BRAZIL NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.2.2 MEXICO NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.2.3 REST OF LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3 WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.1 GERMANY NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.2 FRENCH NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.3 UK NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.4 SPANISH NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.5 ITALY NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.6NORDIC NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.7 BENELUX NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.3.8 REST OF WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.4 EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.4.1 RUSSIA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.4.2 POLAND NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.4.3 REST OF EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5 ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5.1 THE JAPANESE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8. 5.2 THE CHINESE NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5.3 THE INDIAN NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5.4 AUSTRALIA & NEW ZEALAND NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5.6 ASEAN NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.5.7 REST OF ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.6 MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.6.1 GCC COUNTRIES NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.6.2 SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.6.3 NORTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030
8.6.4 REST OF MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET 2020-2030

9. LEADING COMPANIES IN THE NASAL DRUG DELIVERY TECHNOLOGY MARKET
9.1 NOVARTIS AG
9.1.1BUSINESS OVERVIEW
9.1.2COMPANY SNAPSHOT
9.1.3 NOVARTIS AG: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.1.4 NOVARTIS AG: FINANCIALS
9.1.5 NOVARTIS AG: RECENT DEVELOPMENTS
9.2 3M COMPANY
9.2.1BUSINESS OVERVIEW
9.2.2COMPANY SNAPSHOT
9.2.3 3M COMPANY: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.2.4 3M COMPANY: FINANCIALS
9.3 BECTON, DICKINSON AND COMPANY
9.3.1BUSINESS OVERVIEW
9.3.2 COMPANY SNAPSHOT
9.3.3 BECTON, DICKINSON AND COMPANY: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.3.4 BECTON, DICKINSON AND COMPANY: FINANCIALS
9.4 GLAXOSMITHKLINE PLC
9.4.1 BUSINESS OVERVIEW
9.4.2 COMPANY SNAPSHOT
9.4.3 GLAXOSMITHKLINE PLC: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.4.4 GLAXOSMITHKLINE PLC: FINANCIALS
9.4.5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
9.5 JOHNSON & JOHNSON
9.5.1 BUSINESS OVERVIEW
9.5.2 COMPANY SNAPSHOT
9.5.3 JOHNSON & JOHNSON: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.5.4 JOHNSON & JOHNSON: FINANCIALS
9.5.5 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
9.6 MERCK & CO., INC.
9.6.1 BUSINESS OVERVIEW
9.6.2 COMPANY SNAPSHOT
9.6.3 MERCK & CO., INC.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.6.4 MERCK & CO., INC.: FINANCIALS
9.6.5 MERCK & CO., INC.: RECENT DEVELOPMENTS
9.7 PFIZER INC.
9.7.1 BUSINESS OVERVIEW
9.7.2 COMPANY SNAPSHOT
9.7.3 PFIZER INC.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.8 TELEFLEX INCORPORATED
9.8.1 BUSINESS OVERVIEW
9.8.2 COMPANY SNAPSHOT
9.8.3 TELEFLEX INCORPORATED: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.8.4 TELEFLEX INCORPORATED: FINANCIALS
9.9 NAVEH PHARMA LTD.
9.9.1 BUSINESS OVERVIEW
9.9.2 COMPANY SNAPSHOT
9.9.3 NAVEH PHARMA LTD.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.10 B.F. ASCHER & CO., INC.
9.10.1 BUSINESS OVERVIEW
9.10.2 COMPANY SNAPSHOT
9.10.3 B.F. ASCHER & CO., INC.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.11 ENT TECHNOLOGIES PTY LTD
9.11.1 BUSINESS OVERVIEW
9.11.2 COMPANY SNAPSHOT
9.11.3 ENT TECHNOLOGIES PTY LTD: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.12 OPTINOSE US, INC.
9.12.1 BUSINESS OVERVIEW
9.12.2 COMPANY SNAPSHOT
9.12.3 OPTINOSE US, INC.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.12.4 OPTINOSE INC.: FINANCIALS
9.12.5 OPTINOSE US, INC.: RECENT DEVELOPMENTS
9.13 PENDOPHARM
9.13.1 BUSINESS OVERVIEW
9.13.2 COMPANY SNAPSHOT
9.13.3 PENDOPHARM: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.14 APTARGROUP, INC.
9.14.1 BUSINESS OVERVIEW
9.14.2 COMPANY SNAPSHOT
9.14.3 APTARGROUP, INC.: NASAL DRUG DELIVERY TECHNOLOGY PRODUCT PORTFOLIO
9.14.4 APTARGROUP, INC.: FINANCIALS

10. CONCLUSION
10.1 THE WORLD NASAL DRUG DELIVERY TECHNOLOGY MARKET IN 2019 AND 2020
10.2 CURRENT LEADING NASAL DRUG DELIVERY TECHNOLOGY SEGMENTS, BY DOSAGE FORM
10.3 LEADING NASAL DRUG DELIVERY TECHNOLOGY COMPANIES
10.4 LEADING REGIONAL MARKETS
10.5 WORLD NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030
10.6 THE FUTURE OF THE NASAL DRUG DELIVERY TECHNOLOGY MARKET?

11. ABBREVIATION

ASSOCIATED VISIONGAIN REPORTS
VISIONGAIN REPORT SALES ORDER FORM
APPENDIX A
APPENDIX B

LIST OF TABLES
TABLE 1.1 WORLD NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 3.1 DEMOGRAPHIC DEVELOPMENT: INCREASING GROWTH IN THE 65+ POPULATION
TABLE 4.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET BY DOSAGE FORM FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 4.2 DIFFERENT TYPES OF NASAL SPRAYS
TABLE 4.3 NASAL SPRAYS MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 4.4 NASAL SPRAYS MARKET FOR PRESSURIZED CONTAINERS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 4.5 NASAL SPRAYS MARKET FOR NON-PRESSURIZED CONTAINERS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 4.6 NASAL DROPS AND LIQUIDS MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 4.7 NASAL GELS MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 5.2 NASAL POWDERS
TABLE 4.8 NASAL POWDERS MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 5.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET BY SYSTEM FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 5.2 DRUGS FOR UNIT DOSE SYSTEMS
TABLE 5.3 UNIT DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 5.4 BI DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 5.5 DRUGS FOR MULTI-DOSE SYSTEMS
TABLE 5.6 MULTI DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 6.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET BY APPLICATION FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 6.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ASTHMA FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 6.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ALLERGIC AND NON-ALLERGIC RHINITIS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 6.3 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR NASAL CONGESTION FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 6.4 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 7.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET BY END USER FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 7.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ASCS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 7.3 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 7.4 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR SPECIALTY CLINICS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 7.5 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR VACCINATION CENTERS FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.1 NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.2 US NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.4 CANADA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.6 LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.6 BRAZIL NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.7 MEXICO NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.7 REST OF LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.6 WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.6 GERMANY NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.7FRENCH NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.8UK NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.9SPANISH NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.10ITALY NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.10 NORDIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.10 BENELUX NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.10 REST OF WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.11 EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.11 RUSSIA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.12 POLAND NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.13 REST OF EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.11 ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.11JAPANESE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.12CHINESE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.13INDIAN NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.14AUSTRALIA & NEW ZEALAND NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 ASEAN NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 REST OF ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 GCC COUNTRIES NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 NORTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 8.15 REST OF MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
TABLE 9.1 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 9.2 NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 9.3 3M COMPANY: COMPANY SNAPSHOT
TABLE 9.4 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 9.5 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 9.6 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 9.6 JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 9.7 MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 9.8 PFIZER INC.: COMPANY SNAPSHOT
TABLE 9.9 PFIZER INC.: PRODUCT PORTFOLIO
TABLE 9.10 TELEFLEX INCORPORATED: COMPANY SNAPSHOT
TABLE 9.11 NAVEH PHARMA LTD.: COMPANY SNAPSHOT
TABLE 9.12 NAVEH PHARMA LTD.: PRODUCT PORTFOLIO
TABLE 9.13 B.F. ASCHER & CO., INC.: COMPANY SNAPSHOT
TABLE 9.14 B.F. ASCHER & CO., INC.: PRODUCT PORTFOLIO
TABLE 9.15 ENT TECHNOLOGIES PTY LTD: COMPANY SNAPSHOT
TABLE 9.16 ENT TECHNOLOGIES PTY LTD: PRODUCT PORTFOLIO
TABLE 9.17 OPTINOSE US, INC.: COMPANY SNAPSHOT
TABLE 9.18 OPTINOSE US, INC.: PRODUCT PORTFOLIO
TABLE 9.19 PENDOPHARM: COMPANY SNAPSHOT
TABLE 9.20 PENDOPHARMA: PRODUCT PORTFOLIO
TABLE 9.21 APTARGROUP, INC.: COMPANY SNAPSHOT
TABLE 9.22 APTARGROUP, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES
FIGURE 2.1 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION OVERVIEW
FIGURE 3.6 GLOBAL NASAL DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS AND RESTRAINTS
FIGURE 3.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET: PRODUCT LAUNCHES
FIGURE 3.2 PORTER'S FIVE FORCES ANALYSIS OF THE NASAL DRUG DELIVERY TECHNOLOGY MARKET, 2019-2030
FIGURE 4.1 NASAL SPRAYS MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 4.2 NASAL SPRAYS MARKET FOR PRESSURIZED CONTAINERS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 4.3 NASAL SPRAYS MARKET FOR NON-PRESSURIZED CONTAINERS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 4.4 NASAL DROPS AND LIQUIDS MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 4.5 NASAL GELS MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 4.6 NASAL POWDERS MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 5.1 UNIT DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 5.2 BI DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 5.3 MULTI DOSE NASAL DRUG DELIVERY SYSTEM MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 6.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ASTHMA FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 6.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ALLERGIC AND NON-ALLERGIC RHINITIS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 6.3 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR NASAL CONGESTION FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 6.4 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHER APPLICATIONS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 7.1 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR ASCS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 7.2 NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 7.3NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR SPECIALTY CLINICS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 7.4NASAL DRUG DELIVERY TECHNOLOGY MARKET FOR VACCINATION CENTERS FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.1 NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.2 US NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.8CANADA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.10 LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.10 BRAZIL NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.11 MEXICO NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.11 REST OF LATIN AMERICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.10 WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.10GERMANY NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.11 FRENCH NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.12 UK NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.13 SPANISH NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST 2020-2030 (US$M, AGR %, & CAGR %), 2019-2030
FIGURE 8.14 ITALY NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.14 NORDIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.14 BENELUX NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.14 REST OF WESTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.15 EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.15 RUSSIA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.16 POLAND NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.17 REST OF EASTERN EUROPE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.15 ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.15 JAPANESE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.16 CHINESE NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.17 INDIAN NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.18 AUSTRALIA & NEW ZEALAND NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 ASEAN NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 REST OF ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 GCC COUNTRIES NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 NORTH AFRICA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 8.19 REST OF MEA NASAL DRUG DELIVERY TECHNOLOGY MARKET FORECAST: REVENUES ($MILLION) AND AGR (%), 2020-2030
FIGURE 9.1 NOVARTIS AG: REVENUE ($M), 2017-2019
FIGURE 9.2 NOVARTIS AG: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.3 NOVARTIS AG: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.4 3M COMPANY: REVENUE ($M), 2017-2019
FIGURE 9.5 3M COMPANY: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.6 3M COMPANY: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.7 BECTON, DICKINSON AND COMPANY: REVENUE ($M), 2017-2019
FIGURE 9.8 BECTON, DICKINSON AND COMPANY: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.9 BECTON, DICKINSON AND COMPANY: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.10 GLAXOSMITHKLINE PLC: REVENUE (£M), 2017-2019
FIGURE 9.11 GLAXOSMITHKLINE PLC: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.12 GLAXOSMITHKLINE PLC: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.13 JOHNSON & JOHNSON: REVENUE ($M), 2017-2019
FIGURE 9.14 JOHNSON & JOHNSON: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.15 JOHNSON & JOHNSON: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.16 MERCK & CO., INC.: REVENUE ($M), 2017-2019
FIGURE 9.16 MERCK & CO., INC.: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.17 MERCK & CO., INC.: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.18 TELEFLEX INCORPORATED: REVENUE ($M), 2017-2019
FIGURE 9.19 TELEFLEX INCORPORATED: GEOGRAPHICAL SEGMENT % SHARE, 2019
FIGURE 9.20 OPTINOSE INC.: REVENUE, 2018-2019
FIGURE 9.21 APTARGROUP, INC.: REVENUE, 2017-2019
FIGURE 9.22 APTARGROUP, INC.: BUSINESS SEGMENT % SHARE, 2019
FIGURE 9.23 APTARGROUP, INC.: GEOGRAPHICAL SEGMENT % SHARE, 2019

3M Company
Allergy, Asthma and Clinical Immunology
American Academy of Allergy Asthma and Immunology
American Hospital of Paris
American Thoracic Society
AptarGroup, Inc.
Asthma and Allergy Foundation of America
AstraZeneca
Becton, Dickinson and Company
BREATH
Centers for Disease Control and Prevention
Currax Pharmaceuticals LLC
Eli Lilly and Company
European Academy of Allergy and Clinical Immunology (EAACI
Food and Drug Administration
GlaxoSmithKline plc
International Medical Device Regulators Forum (IMDRF)
International Severe Asthma Forum (ISAF
International Study of Asthma and Allergies in Childhood (ISAAC)
International Study of Asthma and Allergies in Childhood (ISAAC)
Johnson & Johnson
Merck & Co., Inc.
Ministry of Health, Labor, and Welfare (MHLW)
National Health Insurance (NHI)
Naveh Pharma Ltd.
Nemera
Neurelis, Inc.
Nordic Severe Asthma Network (NSAN)
OptiNose US, Inc.
Organisation for Economic Cooperation and Development
Pendopharm
Pfizer Inc.
Pharmaceutical Services Negotiating Committee
Pharmaceuticals and Medical Device Agency (PDMA)
Phronesis
Sanofi-aventis
Spanish National Guideline for the Management of Asthma
Teleflex Incorporated
UCB
Upsher-Smith Laboratories
World Allergy Organization Journal
World Health Organization